Sharemaestro company-news research for Veraxa Biotech AG Ordinary Shares (VRXA), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
NASDAQ
United States
Provisional evidence
Company news sentiment
Latest VRXA news and sentiment
Veraxa Biotech AG Ordinary Shares
Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.
Current company news
Early balanced news score
15 company-specific stories are available, but there are not yet enough fresh stories from separate publishers for a firm reading.
Observed headline tone51/100
→
Published 30-day score50/100
Latest source headline
VERAXA Biotech (NASDAQ: VRXA) Advances FDA-Aligned Methods to Reduce Animal Testing
Benzinga · 07 Oct 2026 16:26
Older, less relevant and less reliable stories count for less. Confidence is shown separately.
What supports the score
15 current stories are mapped specifically to VRXA.
The score uses 3 publishers rather than depending on one outlet.
What limits the score
The stories agree, but freshness-weighted evidence is only 0.009.
Confidence is 16/100, below the threshold for a firm score.
50/100
News scoreEarly balanced news score
16/100
Confidencethin evidence
100%/100
Company news15 company stories
93/100
Story agreement7/100 difference
News history
Daily score and story count over 30 days
17 Sep02 Oct16 Oct
News scoreStory count50 baseline
Confidence
How reliable the score is
Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.
Amount of evidence0
0.009 after freshness weightingSource breadth60
3 independent publishersCompany relevance100
share tied directly to this companyFreshness20
recency-weighted evidenceAgreement93
how closely stories agreePublisher mix60
less reliance on one publisherPrice and news history
Weekly price and news-score history
Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.
18 completed price weeks18 comparable news-score weeks
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
12 Jun11 Aug09 Oct
Weekly close, indexedSentiment score
WeekNews scoreCloseWeekly move
09 Oct 202650USD 1.26+11.5%
02 Oct 202650USD 1.13-19.9%
25 Sep 202650USD 1.41-3.4%
18 Sep 202650USD 1.46-11.5%
11 Sep 202651USD 1.65-6.2%
04 Sep 202651USD 1.76+30.4%
28 Aug 202651USD 1.35-30.8%
21 Aug 202650USD 1.95+4.3%
Provisional evidence
News subjects
What is shaping the score
Market update5012 stories · 80%
Regulatory and legal501 stories · 7%
Analyst action501 stories · 7%
Earnings501 stories · 7%
Source mix
Where the evidence comes from
Benzinga434 stories · 27%
TradingView502 stories · 13%
Investing.com571 stories · 7%
Barrons.com501 stories · 7%
Stock Titan501 stories · 7%
Syfe501 stories · 7%
Investing.com UK501 stories · 7%
Recurring subjects
Subjects appearing most often
Life Sciences10Finance6Financial Markets5Earnings5IPO2Biotech2Regulation1Pharma1Oncology1Clinical Trials1
Earlier readings
How the score has changed
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
12 Jun50 neutral16 Oct 15:15
ConstructiveBalanced or withheldCautious
Changes in the stored score
Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.
| Observed | Score | Move | Confidence | Stories | Status |
|---|---|---|---|---|---|
| 16 Oct 15:15 | 50 | +0 | 15/100 (-15) | 15 (-7) | Provisional |
| 07 Oct 23:59 | 50 | +0 | 30/100 (+15) | 22 (-7) | Provisional |
| 30 Sep 23:59 | 50 | +0 | 15/100 (0) | 29 (-1) | Provisional |
| 29 Sep 23:59 | 50 | +0 | 15/100 (-1) | 30 (+1) | Provisional |
| 24 Sep 23:59 | 50 | +0 | 16/100 (0) | 29 (0) | Provisional |
| 23 Sep 23:59 | 50 | +0 | 16/100 (0) | 29 (-3) | Provisional |
| 22 Sep 23:59 | 50 | +0 | 16/100 (-1) | 32 (+1) | Provisional |
| 19 Sep 23:59 | 50 | +0 | 17/100 (0) | 31 (0) | Provisional |
Evidence behind the direction
What drives this reading?
Shares of weighted directional evidence in 15 retained current headlines. These weights already account for freshness, relevance and publisher limits; they are not additive points of the published score.
Which subjects lean each way
A subject can carry both supportive and cautious news.
SubjectCautious ← 0 → Constructive
Market update2 stories
46.1%53.9%
Each side uses the same scale: 0–53.9% of the retained directional evidence.
Where the influence comes from
53.9%largest publisher shareA concentrated reading can depend heavily on one publisher.
Publisher groups follow the scoring rules. Company disclosures share one group; syndicated stories are consolidated before weighting.
Source headlines
The news behind the score
Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.
43/100 tone
46.1% of directional evidence
Low story strength
Scoring detailsDirect company coverage
- Published
- 07 Oct 2026 16:26
- News subject
- Market update
- Why this score
- Negative financial language
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Low · 34/100
- 30-day weight
- 46.1% of directional evidence · 9.0d old
- Text assessed
- Available headline and article text
- Duplicates
- 2 consolidated
—Unscored
Regulatory and legalNot used in direction
This Tiny Biotech Stock Is Down 96% This Year. Can Next-Gen Drug Testing Save It?
Veraxa is shifting away from animal testing to get drugs to market faster, calling it ‘not just a regulatory obligation, but a scientific opportunity.’ Continue Reading
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Veraxa is shifting away from animal testing to get drugs to market faster, calling it ‘not just a regulatory obligation, but a scientific opportunity.’ Continue Reading
- Published
- 07 Oct 2026 13:58
- News subject
- Regulatory and legal
- Why this score
- No clear directional signal in the available text
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 9.1d old
- Text assessed
- Available headline and article text
- Duplicates
- 3 consolidated
BiotechClinical TrialsPharmaRegulation
57/100 tone
53.9% of directional evidence
Low story strength
Scoring detailsDirect company coverage
- Published
- 07 Oct 2026 13:07
- News subject
- Market update
- Why this score
- Positive financial language
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Low · 34/100
- 30-day weight
- 53.9% of directional evidence · 9.1d old
- Text assessed
- Available headline and article text
- Duplicates
- 2 consolidated
—Unscored
Market updateNot used in direction
VERAXA Biotech Provides Overview on Implementation of FDA-Aligned Human-Relevant Models into R&D Strategy
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 07 Oct 2026 11:00
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 9.2d old
- Text assessed
- Available headline and article text
- Duplicates
- 2 consolidated
—Unscored
Market updateNot used in direction
Veraxa Biotech AG (VRXA) Stock Price & News
This article provides an overview of Veraxa Biotech AG (VRXA) stock performance and company information. As of October 2nd, the stock was trading at US$1.13, down 5.04%, with a market capitalization of US$275.75M. The company, founded on June 25, 2025, focuses on developing antibody-based…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
This article provides an overview of Veraxa Biotech AG (VRXA) stock performance and company information. As of October 2nd, the stock was trading at US$1.13, down 5.04%, with a market capitalization of US$275.75M. The company, founded on June 25, 2025, focuses on developing antibody-based drug platforms for cancer treatment and has had several recent positive announcements.
- Published
- 30 Sep 2026 15:27
- News subject
- Market update
- Why this score
- Positive financial language
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 16.0d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
EarningsFinancial MarketsLife Sciences
—Unscored
Market updateNot used in direction
Form 4 Veraxa Biotech AG For: 29 September By Investing.com
The article reports on a Form 4 filing for Veraxa Biotech AG, indicating insider transaction activity for September 29th. It is a brief, factual announcement from Investing.com, providing the date of the filing and the company involved.
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
The article reports on a Form 4 filing for Veraxa Biotech AG, indicating insider transaction activity for September 29th. It is a brief, factual announcement from Investing.com, providing the date of the filing and the company involved.
- Published
- 29 Sep 2026 21:32
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 16.7d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
EarningsFinanceLife Sciences
—Unscored
Market updateNot used in direction
Weekly Recap: Veraxa Biotech (VRXA) NASDAQ debut and leadership hires
Veraxa Biotech (VRXA) recently began trading on NASDAQ after a business combination in June 2026. The company is focused on advancing its oncology pipeline and seeking industrial partners for its technology platforms. Additionally, Veraxa Biotech strengthened its leadership team with the …
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Veraxa Biotech (VRXA) recently began trading on NASDAQ after a business combination in June 2026. The company is focused on advancing its oncology pipeline and seeking industrial partners for its technology platforms. Additionally, Veraxa Biotech strengthened its leadership team with the appointment of Raju Willener as CFO and Christoph Erkel, Ph.D., as CSO to oversee finance and antibody development, respectively.
- Published
- 29 Sep 2026 01:01
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 17.6d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
FinanceIPOLife Sciences
—Unscored
Analyst actionNot used in direction
Veraxa Biotech AG (VRXA) Stock Price | Live Quotes & Charts | NASDAQ
The article provides real-time stock quotes and charts for Veraxa Biotech AG (VRXA), showing its current price at $1.41, up $0.05 (3.55%). It notes that there is no analyst rating or earnings information available for the company. The page also features promotional content for a stock tra…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
The article provides real-time stock quotes and charts for Veraxa Biotech AG (VRXA), showing its current price at $1.41, up $0.05 (3.55%). It notes that there is no analyst rating or earnings information available for the company. The page also features promotional content for a stock trading bootcamp and an AI-driven trading analysis tool.
- Published
- 25 Sep 2026 02:02
- News subject
- Analyst action
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 21.6d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
EarningsFinancial MarketsLife Sciences
—Unscored
Market updateNot used in direction
VERAXA Biotech (NASDAQ: VRXA) Advances Oncology Pipeline as Xlife Sciences Reports First-Half Progress
VERAXA Biotech (VRXA) is focusing on advancing its oncology pipeline and forging industrial partnerships after securing financing and commencing Nasdaq trading in June 2026. Xlife Sciences AG, VERAXA's parent company, reported significant operational and scientific progress across its por…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
VERAXA Biotech (VRXA) is focusing on advancing its oncology pipeline and forging industrial partnerships after securing financing and commencing Nasdaq trading in June 2026. Xlife Sciences AG, VERAXA's parent company, reported significant operational and scientific progress across its portfolio in the first half of 2026, including developments in diagnostics and AI. Xlife Sciences plans to continue supporting VERAXA in establishing industry partnerships and pursuing commercialization efforts for the remainder of 2026.
- Published
- 24 Sep 2026 15:42
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 22.0d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
EarningsLife Sciences
—Unscored
Market updateNot used in direction
Weekly Recap: BiTAC dual-targeting selectivity and Raju Willener CFO hire
Veraxa Biotech AG (VRXA) is making strides in its oncology pipeline by developing BiTAC, a dual-targeting platform designed to improve tumor selectivity by only triggering cytotoxicity when two tumor antigens are engaged. Additionally, the company has appointed Raju Willener as its new CF…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Veraxa Biotech AG (VRXA) is making strides in its oncology pipeline by developing BiTAC, a dual-targeting platform designed to improve tumor selectivity by only triggering cytotoxicity when two tumor antigens are engaged. Additionally, the company has appointed Raju Willener as its new CFO to lead its financial and capital markets strategies as it advances its research.
- Published
- 23 Sep 2026 01:28
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Company discussed · 86%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 23.6d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Life SciencesFinance
—Unscored
Market updateNot used in direction
VERAXA Biotech (NASDAQ: VRXA) Builds Oncology Pipeline Around BiTAC Platform, Public-Market Story Enters
VERAXA Biotech, trading on NASDAQ under VRXA since June 2026, is advancing its oncology pipeline, focusing on its proprietary BiTAC® platform and other antibody-drug conjugate technologies. The company has reported early preclinical evidence for its BiTAC-TCE and BiTAC-ADC approaches and …
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
VERAXA Biotech, trading on NASDAQ under VRXA since June 2026, is advancing its oncology pipeline, focusing on its proprietary BiTAC® platform and other antibody-drug conjugate technologies. The company has reported early preclinical evidence for its BiTAC-TCE and BiTAC-ADC approaches and has recently strengthened its leadership with key appointments in finance and scientific development. VERAXA's strategy centers on an "AND-gated" therapeutic approach designed to activate cytotoxic mechanisms only when two complementary components engage the same cancer cell.
- Published
- 22 Sep 2026 11:10
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 24.2d old
- Text assessed
- Stored article
- Duplicates
- 2 consolidated
BiotechFinanceFinancial MarketsIPOLife SciencesOncology
—Unscored
EarningsNot used in direction
Veraxa Biotech AG (VRXA) Stock Price | Live Quotes & Charts | NASDAQ
This page provides live quotes and charts for Veraxa Biotech AG (VRXA) stock, showing its current price and daily performance. It also includes sections for analyst ratings, indicating no ratings available in the last three months, and states that earnings information for Veraxa Biotech A…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
This page provides live quotes and charts for Veraxa Biotech AG (VRXA) stock, showing its current price and daily performance. It also includes sections for analyst ratings, indicating no ratings available in the last three months, and states that earnings information for Veraxa Biotech AG is not currently available. The article is hosted on a financial education platform by Timothy Sykes, a penny stock trader, and contains extensive disclaimers about the risks of day trading.
- Published
- 19 Sep 2026 02:29
- News subject
- Earnings
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 27.5d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
EarningsFinancial MarketsLife Sciences
—Unscored
Market updateNot used in direction
VERAXA Biotech (NASDAQ: VRXA) Adds Capital Markets Veteran as CFO While Advancing BiTAC Oncology Pipeline
VERAXA Biotech (VRXA) has appointed Raju Willener as its new Chief Financial Officer, effective immediately. Willener brings over 30 years of international experience in investment banking, corporate finance, and asset management. His appointment comes as VERAXA continues to advance its p…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
VERAXA Biotech (VRXA) has appointed Raju Willener as its new Chief Financial Officer, effective immediately. Willener brings over 30 years of international experience in investment banking, corporate finance, and asset management. His appointment comes as VERAXA continues to advance its proprietary BiTAC platform and oncology pipeline, which has shown encouraging early data.
- Published
- 18 Sep 2026 18:03
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 27.9d old
- Text assessed
- Stored article
- Duplicates
- 2 consolidated
FinanceLife Sciences
—Unscored
Market updateNot used in direction
VRXA Price Today: Veraxa Biotech AG Stock Price, Quote & Chart | MEXC
This article provides a detailed overview of Veraxa Biotech AG (VRXA) stock performance, including its current price, market capitalization, and 52-week trading range. It also explains how to purchase VRXA stock on MEXC's RealStocks platform and offers company information, highlighting it…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
This article provides a detailed overview of Veraxa Biotech AG (VRXA) stock performance, including its current price, market capitalization, and 52-week trading range. It also explains how to purchase VRXA stock on MEXC's RealStocks platform and offers company information, highlighting its focus on antibody therapies and oncology.
- Published
- 18 Sep 2026 14:00
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 28.1d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
FinanceFinancial MarketsLife Sciences
—Unscored
Market updateNot used in direction
VERAXA Biotech (NASDAQ: VRXA) Building a New Approach to Precision Cancer Therapy
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 16 Sep 2026 16:01
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 30.0d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
Earlier company news
VRXA news archive
Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.
Older news is kept in the archive
There are 69 older VRXA headlines. Open one page at a time when you need them.
Open older archiveProvider matches checked
Provider mentions not used in the score
A news provider linked these stories to VRXA, but the headline and available text are not mainly about Veraxa Biotech AG Ordinary Shares. They are kept here for transparency and do not affect the score, confidence, history or wider market totals.
Provider mentions are kept separate
Open the list to see which provider matches were checked and left out of VRXA sentiment.
Open provider mentionsHow the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme. This is a rule-based evidence measure, not a calibrated probability.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
It measures news already published. It is not a forecast, recommendation or price target.